The aim of this study was to demonstrate the differences in salbutamol's bronchodilating effect related to administration routes of the drug. Three different administration routes were assessed: salbutamol given by a MDI device, a nebulizer and intravenously. The following increases of FEV1 were seen after administration routes: MDI--12%, nebuliser--27%, intravenously--22%. These differences were statistically significant.